Trevi Therapeutics Inc (TRVI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Trevi Therapeutics Inc (TRVI) has a cash flow conversion efficiency ratio of -0.054x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.43 Million) by net assets ($321.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Trevi Therapeutics Inc for the company's overall valuation and market capitalisation.
Trevi Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Trevi Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Trevi Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trevi Therapeutics Inc ranked by their cash flow conversion efficiency. See TRVI debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BrightGene Bio Medical Technology C
SHG:688166
|
0.010x |
|
CARL ZEISS MEDITEC ADR 1
F:AFXA
|
0.008x |
|
SolarEdge Technologies Inc
NASDAQ:SEDG
|
0.059x |
|
CENTRAL PUERTO ADR/1 AP1
F:C3TA
|
0.074x |
|
Pandox AB (publ)
ST:PNDX-B
|
0.016x |
|
Shenzhen Expressway Co Ltd
SHG:600548
|
0.039x |
|
Freehold Royalties Ltd.
TO:FRU
|
0.055x |
|
Western Union Co
NYSE:WU
|
0.115x |
Annual Cash Flow Conversion Efficiency for Trevi Therapeutics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Trevi Therapeutics Inc from 2016 to 2025. View latest Trevi Therapeutics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $183.24 Million | $-42.09 Million | -0.230x | +40.17% |
| 2024-12-31 | $99.64 Million | $-38.26 Million | -0.384x | +0.06% |
| 2023-12-31 | $82.55 Million | $-31.71 Million | -0.384x | -46.51% |
| 2022-12-31 | $107.46 Million | $-28.18 Million | -0.262x | +84.53% |
| 2021-12-31 | $17.07 Million | $-28.95 Million | -1.695x | -59.48% |
| 2020-12-31 | $27.28 Million | $-29.00 Million | -1.063x | -151.07% |
| 2019-12-31 | $54.55 Million | $-23.09 Million | -0.423x | +59.94% |
| 2018-12-31 | $17.31 Million | $-18.29 Million | -1.057x | -95.84% |
| 2017-12-31 | $14.78 Million | $-7.97 Million | -0.540x | -183.95% |
| 2016-12-31 | $-17.41 Million | $-11.19 Million | 0.643x | -- |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction i… Read more